Company Encyclopedia
View More
name
Labway
301060.SZ
Shanghai Labway Clinical Laboratory Co., Ltd. engages in the sale of in-vitro diagnostic products in China. The company distributes in-vitro diagnostic instruments, reagents, and related accessories and consumables. It also provides third-party medical testing, pathological diagnosis services, precision medicine, CRO, and sample bank laboratory services; scientific research technology and testing; and professional technical support services.
400.53 B
301060.SZMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
C
Health Care DistributorsIndustry
Industry Ranking18/25
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-4.20%D
    • Profit Margin-4.56%D
    • Gross Margin29.71%C
  • Growth ScoreD
    • Revenue YoY-11.61%E
    • Net Profit YoY61.65%B
    • Total Assets YoY-8.92%E
    • Net Assets YoY-12.66%E
  • Cash ScoreE
    • Cash Flow Margin-2192.52%E
    • OCF YoY-11.61%E
  • Operating ScoreB
    • Turnover0.6B
  • Debt ScoreB
    • Gearing Ratio31.28%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Labway: Net profit in the third quarter was 5.1154 million yuan, a year-on-year increase of 109.11%

    Labway announced that its revenue for the third quarter was 343 million yuan, a year-on-year decrease of 20.63%; net profit was 5.1154 million yuan, a year-on-year increase of 109.11%. Revenue for the first three quarters was 1.102 billion yuan, a year-on-year decrease of 16.51%; net profit recorded a loss of 667,700 yuan, a year-on-year decrease of 98.35%

    Zhitong·
    SZ
    301060
    -2.03%
    Zhitong·
    SZ
    301060
    -2.03%

    Labway: Appointed Wu Chuanjiang as the company's deputy general manager

    36Kr learned that Labway announced that the sixth meeting of the fourth board of directors reviewed and approved the "Proposal on the Appointment of the Company's Deputy General Manager," agreeing to appoint Wu Chuanjiang as the company's deputy general manager, with a term starting from the date of approval by the sixth meeting of the fourth board of directors until the end of the fourth board of directors' term

    36Kr·
    SZ
    301060
    -2.03%
    36Kr·
    SZ
    301060
    -2.03%

    Labway released its first-quarter performance, turning from profit to a loss of 8.0809 million yuan

    According to the Zhitong Finance APP, Labway released its first quarter report for 2025, showing an operating income of 351 million yuan, a year-on-year decrease of 19.60%. The net loss attributable to shareholders of the listed company was 8.0809 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 10.874 million yuan. The basic loss per share was 0.0203 yuan

    Zhitong·
    SZ
    301060
    -2.03%
    Zhitong·
    SZ
    301060
    -2.03%

    Labway announced a preliminary loss, expecting a net loss of 107 million to 157 million yuan for the fiscal year 2024

    According to the Zhitong Finance APP, Labway released its performance forecast for 2024, expecting a net loss attributable to shareholders of the listed company to be between 107 million yuan and 157 million yuan for the whole year. During the reporting period, the collection of long-aged accounts receivable from some testing businesses led to a significant decrease in the credit impairment losses recognized this year compared to the same period last year

    Zhitong·
    SZ
    301060
    -2.03%
    Zhitong·
    SZ
    301060
    -2.03%

    Monkeypox concept stocks rise as China reports a cluster outbreak of the Ib sublineage of the monkeypox virus

    Monkeypox concept stocks rose due to news of the epidemic, with Labway hitting the daily limit, and DAJY also reaching the daily limit. The Chinese Center for Disease Control and Prevention reported a cluster outbreak of monkeypox virus Ib sub-branch, originating from a foreign individual with a travel history to Congo. The national and multiple provincial governments have activated a joint prevention and control mechanism, identifying 4 related cases, with mild symptoms, and the outbreak has been effectively managed

    Zhitong·
    SZ
    301060
    -2.03%
    SZ
    002030
    -0.65%
    Zhitong·
    SZ
    301060
    -2.03%
    SZ
    002030
    -0.65%
    © 2025 Longbridge｜Disclaimer